To investigate the combinatorial effects of targeting both AKT and Src signaling in PTEN-deficient cancer cells, we treated MCF10A-PTEN-KO cells with different concentrations of the Src inhibitor dasatinib (from 0 to 120 nM) and AKT inhibitor capivasertib (from 0 to 100 μM), assessed proliferation, and performed synergy analysis. This evidence concerns the gene AKT1 and cancer.